VIDEO: COMMIT study accruing first-line patients with MSI-high colorectal cancer
Click Here to Manage Email Alerts
In this video, Howard S. Hochester, MD, discusses the COMMIT study comparing the anti-PD1 drug atezolizumab with atezolizumab combined with FOLFOX chemotherapy presented as part of a poster session at ASCO Annual Meeting.
"When we started this study, it wasn't known if it was better to give chemotherapy or immunotherapy, an anti-PD1 drug — in this study it was atezolizumab — or to give the combination," Hochester, associate director for clinical research and director of GI Oncology at Rutgers Cancer Institute, said.
The study evaluated three arms, including chemotherapy alone; however, research was suspended last year after the results of KEYNOTE-177 showed that pembrolizumab was superior to physician choice of chemotherapy, Hochester said. In response, he and his colleagues eliminated the chemotherapy alone arm and looked at only atezolizumab alone vs. combined FOLFOX chemotherapy.
"We are continuing to accrue, so if you do have new first-line patients with colorectal cancer, please check them for their microsatellite-high status or mismatch repair deficiency, and if they are MSI-high, then they could be enrolled in this study," Hochester said.
The study is still enrolling at several hundred hospitals across the United States through the sponsorship of National Clinical Trials Network.
Collapse
Read more about
Click Here to Manage Email Alerts